Miyant'e Newton , Richard Kris


Cancer is still one of the leading causes of death in the US today. With the continuous advances in science and technology, new drugs are being produced to help treat cancer. However, there is still no good treatment for certain kinds of cancer such as pancreatic cancer. Treatment is surgery along with gemcitabine, a nucleoside analog that is used in chemotherapy in various types of cancers. Although gemcitabine inarguably has an effect on those cancers, it also causes an effect on rapidly growing cells, not just those cells affected by cancer, as can be seen by the side effects that occur in patients that undergo chemotherapy. One goal of our research is to find a compound that will complement the effects of gemcitabine and allow the gemcitabine to be used at a lower concentration to help ameliorate side effects.

                Approximately 20,000 compounds from the National Cancer Institute were tested. They were first organized into thirty-two 384 well plates, with eight plates in each quadrant. Using the Titer-Blue cell assay, the effects of these compounds in addition to gemcitabine were measured to determine which compounds inhibited  the growth of MIA and CFPAC cells. From these tests, the eight compounds in the hit wells of the 384 well plates were retested as individual compounds. Specificity of a compound was determined by comparing its inhibition of growth of  pancreatic cancer cells to normal cells. Results will be shown for the best compounds that were able to affect the activity of gemcitabine.

This Work was supported by a NSF SBIR Phase II grant IIP-1127476 (NuvoGen Research, LLC).

Conference Home | List of Abstracts | Photo Gallery